ABSTRACT
Aim: Although most patients with COVID-19 experience respiratory tract infections, severe reactions to the virus may cause coagulation abnormalities that mimic other systemic coagulopathies associated with severe infections, such as disseminated intravascular coagulation and thrombotic microangiopathy. Fluctuations in platelet markers, which are an indicator of the acute phase response for COVID-19, are of clinical importance. The aim of this study is to evaluate the relationship between disease severity and Platelet Mass Index (MPI) parameters in COVID-19 patients. Material(s) and Method(s): This retrospective observational study was conducted with patients who were diagnosed with COVID-19 in a tertiary hospital. The study was continued with the remaining 280 patients. All laboratory data were scanned retrospectively from patient files and hospital information system. Result(s): A very high positive correlation was found between PMI and PLT. The PMI value in women was significantly higher than in men. It was observed that PMI did not differ significantly in terms of mortality, intubation, CPAP and comorbidity. PMI vs. Pneumonia Ct Severity Score, biochemistry parameters (AST, CRP), hemogram parameters (WBC, HGB, HCT, MCV, LYM, MPV EO) and coagulation factors (aPTT and FIB) at various levels of positive/negative, weak and strong, and significant relationship was found. There was no significant relationship between hormone and D-dimer when compared with PMI. Discussion(s): Although platelet count alone does not provide information about the prognosis of the disease, PMI may guide the clinician as an indicator of lung damage in seriously ill patients.Copyright © 2022, Derman Medical Publishing. All rights reserved.
ABSTRACT
Aim: Although most patients with COVID-19 experience respiratory tract infections, severe reactions to the virus may cause coagulation abnormalities that mimic other systemic coagulopathies associated with severe infections, such as disseminated intravascular coagulation and thrombotic microangiopathy. fluctuations in platelet markers, which are an indicator of the acute phase response for COVID-19, are of clinical importance. The aim of this study is to evaluate the relationship between disease severity and Platelet Mass Index (MPI) parameters in COVID-19 patients. Material and Methods: This retrospective observational study was conducted with patients who were diagnosed with COVID-19 in a tertiary hospital. The study was continued with the remaining 280 patients. All laboratory data were scanned retrospectively from patient files and hospital information system. Results: A very high positive correlation was found between PMI and PLT. The PMI value in women was significantly higher than in men. It was observed that PMI did not differ significantly in terms of mortality, intubation, CPAP and comorbidity. PMI vs. Pneumonia Ct Severity Score, biochemistry parameters (AST, CRP), hemogram parameters (WBC, HGB, HCT, MCV, LYM, MPV EO) and coagulation factors (aPTT and FIB) at various levels of positive/negative, weak and strong, and significant relationship was found. There was no significant relationship between hormone and D-dimer when compared with PMI. Discussion: Although platelet count alone does not provide information about the prognosis of the disease, PMI may guide the clinician as an indicator of lung damage in seriously ill patients
ABSTRACT
Introduction: Immunocompromised patients, SARS-CoV-2 infection might have a more severe course and may cause pneumonia quicker, compared to normal hosts. The presence of comorbid diseases increases this risk even further. In our study, we aimed to determine the clinical course and severity of COVID-19 in immunocompromised patients. Materials and method: Our study was carried out between 01 April 2020 and 01 October 2020 in 4 centers as a retrospective case-control study. Firstly, COVID-19 positive patients with previous immunosuppressive disorder diagnosis or patients who use immunosuppressive medicines for any reason were enrolled in the case group. COVID-19 rtRT-PCR positive patients who have no previous immunosuppressive disorder diagnosis and who are not on any immunosuppressive medicines were enrolled in the control group. Definitive statistical analysis was conducted for all of the researched variables. Results: 156 immunocompromised patients with COVID-19 diagnosis were enrolled in the case group of patients and 312 non-immunocompromised patients with COVID-19 diagnosis were enrolled in the control groups. In immunocompromised patients, CMI scores, the prevalence of hypertension, respiratory rate/minute, shortness of breath, and weakness were high and complaints about fever were low. In these patients, CRP, D-dimer, ferritin, and troponin values were high at statistically significant levels and lymphocyte values were low. The need for intensive care for immunocompromised patients was 2.93 times more and nosocomial infections and thrombotic complications occurred more frequently. Mortality was 3.57 times higher in immunocompromised patients. Conclusion: SARS-CoV-2 has a more severe course in immunocompromised patients. However, when evaluating these patients, whether or not the underlying diseases are under control should be evaluated and thrombotic complications and nosocomial infections should be taken into account. © 2021 A. CARBONE Editore. All rights reserved.
ABSTRACT
Background: In SARS-COV-2 disease, anosmia and dysgeusia are symptoms that are usually detected together. In our study, it was aimed to investigate the impairments in the sense of smell and taste in our COVID-19 patients and to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the parameters accompanying this impairment. Methods: The study was conducted retrospectively in patients with positive COVID-19 rtRT-PCR test, whose complaints of smell-taste dysfunction were questioned in 6 centers. Result: 8238 patients questioned for the impaired sense of smell and taste were included in our study. 1756 (21.3%) patients had smell-taste dysfunction. Smell dysfunction started 2.9±2.3 days after the onset of COVID-19 specific symptoms and continued for 9.4±2.7 days. There was a positive correlation between the disturbance of smell and taste and the complaints of fever, sore throat, myalgia, weakness, headache, and negative correlation the complaints of cough. 218 (12.4%) of the patients with smell-taste dysfunction stated that this complaint negatively affected their quality of life. Conclusion: Smell-taste dysfunction is more common, especially with the symptoms of upper respiratory tract infection of COVID-19, and has a positive correlation with fever, sore throat, myalgia, weakness, and headache, affects the quality of life of patients and improves in about 10-14 days. © 2021 A. CARBONE Editore. All rights reserved.